Corticosteroids for OPRA: Dose Equivalence, Steroid Tapering & HPA Axis Suppression

Relative potency and equivalent doses

Corticosteroids differ substantially in glucocorticoid potency, mineralocorticoid (salt-retaining) activity, and duration of action — none of which scale together. Hydrocortisone is the reference point (glucocorticoid potency = 1) but carries meaningful mineralocorticoid activity; dexamethasone and betamethasone are far more potent glucocorticoids but have essentially none. This is why a patient can't simply be switched between agents on a flat mg-for-mg basis — the equivalent-dose table below is the one to reason from. These ratios are a well-established pharmacological approximation, not a precise clinical dosing instruction — individual dose adjustments still depend on the clinical indication.

Why duration and dose — not the diagnosis — determine risk

• Most patients receiving systemic corticosteroids for less than 2–3 weeks can stop without tapering, provided they haven't had repeated recent courses or other risk factors for HPA suppression — this is a general pattern, not an absolute rule, and OPRA scenarios can test the exceptions.
• Doses at or below the physiological replacement range don't suppress the axis regardless of duration — approximately 5 mg/day prednisolone equivalent, though some references quote up to 7.5 mg/day, so treat this as a working range rather than a fixed cutoff.
• Longer courses at supraphysiological doses, or repeated short courses close together, are what create real suppression risk — that's the actual trigger for a taper, not the underlying condition being treated.

Prednisone vs. prednisolone

Prednisone is a prodrug that requires hepatic conversion to its active form, prednisolone, before it works. In significant liver disease that conversion can be impaired, so prednisolone (already active) is generally preferred over prednisone in that setting. Australian practice uses prednisolone far more often than prednisone for this reason — a useful distinction to keep straight, since the two names are easy to confuse under time pressure.

Practise this topic

Reading through the concepts above is the first step — the equivalence calculations and taper-vs-stop judgment calls are what actually get tested, and both take practice under exam-style conditions. Practise more Pharmacology and Therapeutics OPRA questions with ClinicalStem's OPRA question bank.

Deciding whether to taper

The scenario detail that matters is course length and dose, not diagnosis. A patient on prednisolone 50 mg/day for 5 days for an asthma flare can generally stop abruptly. A patient on prednisolone 10 mg/day for 4 months for an autoimmune condition needs a structured taper — abrupt cessation risks an adrenal crisis (hypotension, hypoglycaemia, severe fatigue, potentially life-threatening). Between those extremes, use the duration/dose thresholds above rather than intuition about the underlying disease.

Monitoring long-term systemic therapy

• Blood glucose and HbA1c — corticosteroids are hyperglycaemic and can precipitate or worsen diabetes; more frequent monitoring in patients with, or at risk of, diabetes.
• Blood pressure and fluid status — particularly with agents carrying mineralocorticoid activity (e.g. hydrocortisone, cortisone).
• Weight/BMI — corticosteroids commonly drive weight gain and fluid retention over a long course.
• Bone density — long-term therapy increases fracture risk; calcium/vitamin D and, where indicated, a bisphosphonate for osteoporosis prevention are considered for extended courses.
• Eyes — cataracts and raised intraocular pressure with prolonged use.
• Mood and psychiatric effects — can range from mild irritability to significant mood disturbance.
• Infection risk — corticosteroids can blunt the usual signs of infection (including fever), so a muted inflammatory response doesn't rule infection out.

Vaccination in patients on immunosuppressive doses

Live vaccines are generally avoided in patients receiving immunosuppressive doses of systemic corticosteroids, because the vaccine strain can replicate more freely when the immune response that normally contains it is suppressed. Inactivated vaccines don't carry this specific concern and can generally proceed as normal.

Stress dosing around illness and surgery

Patients with adrenal suppression require perioperative glucocorticoid supplementation because they cannot mount an endogenous cortisol response to physiological stress (acute illness, trauma or surgery). The specific increase depends on the procedure or illness severity, so the exam-relevant skill is recognising when perioperative glucocorticoid supplementation is indicated, not memorising one fixed regimen.

Alternate-day dosing

For some chronic conditions, giving the total corticosteroid dose every other day (rather than daily) can reduce HPA-axis suppression compared with an equivalent daily dose, since it allows the axis to partially recover on the off day. It isn't appropriate for every condition — some require steady daily levels for disease control — so it's an option to be aware of rather than a default approach.

Inhaled and topical corticosteroids

• Advise patients to rinse the mouth (and spit, not swallow) after using an inhaled corticosteroid, to reduce the risk of oral candidiasis (thrush) — a classic OPRA counselling point.
• Topical corticosteroid potency depends on both the specific formulation and the body site it's applied to — thin-skin areas (face, flexures) absorb more for a given potency than thicker-skin areas (palms, soles), so "the same" product can behave very differently by site. Not all topical steroids are interchangeable.

Can inhaled corticosteroids cause the same problems as oral ones?

At high doses and with prolonged use, inhaled corticosteroids can be absorbed systemically enough to cause HPA-axis suppression and other systemic effects — it's a matter of degree (much lower risk at standard doses) rather than a difference in kind from oral therapy.

Is there one single tapering schedule used for every patient stopping long-term corticosteroids?

No — the specific taper is individualised to the dose, duration of therapy, and clinical context. The exam-relevant point is recognising *that* a taper is needed once duration/dose crosses the low-risk threshold, not memorising one universal schedule.